Long-term results of radiotherapy in anaplastic thyroid cancer

Radiation Oncology

Dirk Vordermark¹  Tanja Pelz¹  Anne-Katrin Dumke¹ 

[1]Department of Radiation Oncology, Martin Luther University Halle-Wittenberg, Dryanderstr. 4, 06110 Halle (Saale), Germany

关键词: Long-term survival;    Prognostic factors;    Multimodal therapy;    Radiotherapy;    Undifferentiated thyroid cancer (UTC);    Anaplastic thyroid cancer (ATC);   

Others  :  810373
DOI  :  10.1186/1748-717X-9-90

 received in 2013-08-03, accepted in 2014-03-16,  发布年份 2014

【 摘 要 】

Background

Anaplastic thyroid cancer (ATC) is an aggressive malignant tumour with a poor prognosis. The median overall survival is described in the literature to be just 6 months, however, in series of selected patients treated by multimodal therapy cases of long-time-survival have been reported. We analyzed the role of radiotherapy and the impact of other therapies and clinical features on survival in patients with ATC.

Methods

In a retrospective analysis of all patients (n = 40), who presented with histologically proven ATC at a single centre between 1989 and 2008, patient and treatment characteristics with a focus on details of radiotherapy were registered and the survival status determined.

Results

39 of 40 patients received radiotherapy, 80% underwent surgery and 15% had chemotherapy. The median dosis of radiation was 50 Gy (6–60.4 Gy), in 87.5% fractionation was once daily. In 49.4% opposing-field techniques were applied, in 14% 3D-conformal-techniques and 32.5% combinations of both.

The median overall survival (OS) was 5 months, 1-year survival 35.2% and 5-year-survival 21.6%. Interestingly, 24.3% survived 2 years or longer. Three factors could be identified as predictors of improved overall survival: absence of lymph node metastasis (N0) (median OS 18.3 months), median dose of radiation of 50 Gy or more (median OS 10.5 months) and the use of any surgery (median OS 10.5 months).

Conclusions

Despite the generally poor outcome, the combination of surgery and intensive radiotherapy can result in long-term survival in selected patients with ATC.

【 授权许可】

   
2014 Dumke et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Are C, Ashok RS: Educational review anaplastic thyroid carcinoma: biology, pathogenesis, prognostic factors, and treatment approaches. Ann Surg Oncol 2006, 13:453-464.
• [2]Taccaliti A, Silvetti F, Palmonella G, Boscaro M: Anaplastic thyroid carcinoma. Front Endocrinol 2012, 3:84.
• [3]Schmid KW: Pathogenese, klassifikation und histologie von schilddrüsenkarzinomen. Onkologe 2010, 16:644-656.
• [4]Lim SM, Shin SJ, Chung WY, Park CS, Nam KH, Kang SW, Keum KC, Kim JH, Cho JY, Hong YK, Cho BC: Treatment outcome of patients with anaplastic thyroid cancer: a single center experience. Yonsei Med J 2012, 53(2):352-357.
• [5]Koussis H, Maruzzo M, Scola A, Eric CI, Fassina A, Marioni G, Lora O, Corti L, Karachontziti P, Jirillo A: A case of anaplastic thyroid cancer with long-term survival. Anticancer Res 2010, 30(4):1273-1278.
• [6]Lim KH, Lee KW, Kim JH, Park SY, Choi SH, Lee JS: Anaplastic thyroid carcinoma initially presented with abdominal cutaneous mass and hyperthyroidism. Korean J Intern Med 2010, 25(4):450-453.
• [7]Chang HS, Nam KH, Chung WY, Park CS: Anaplastic thyroid carcinoma: a therapeutic dilemma. Yonsei Med J 2005, 46(6):759-764.
• [8]Sautter-Bihl ML, Reiners C: Schilddrüsenkarzinom. In Radioonkologie Band 2. Edited by Herausgegeben von Bamberg , Molls , Sack . München: Zuckschwerdt-Verlag; 2009:281-293. [2. Aufl]
• [9]Smallridge RC, Ain KB, Asa SL, Bible KC, Brierly JD, Burman KD, Kebebew E, Lee NY, Nikiforov YE, Rosenthal MS, Shah MH, Shaha AR, Tuttle RM: American thyroid association guidelines for management of patients with anaplastic thyroid cancer for the American thyroid association anaplastic thyroid cancer guidelines taskforce. Thyroid 2012, 22(11):1104-1139.
• [10]Sobin LH, Gospodarowicz MK, Wittekind C: UICC TNM-classification of malignant tumours. 7th edition. Oxford: Wiley-Blackwell; 2009.
• [11]Derbel O, Limem S, Ségura-Ferlay C, Lifante JC, Carrie C, Peix JL, Borson-Chazot F, Bournaud C, Droz JP, de la Fouchardiére C: Results of combined treatment of anaplastic thyroid carcinoma (ATC). BMC Cancer 2011, 11:469.
• [12]Segerhammar I, Larsson C, Nilsson IL, Bäckdahl M, Höög A, Wallin G, Foukakis T, Zedenius J: Anaplastic carcinoma of the thyroid gland: treatment and outcome over 13 years at one institution. J Surg Oncol 2012, 106(8):981-986.
• [13]Smallridge RC, Copland JA: Anaplastic thyroid carcinoma: pathogenesis and emerging therapies. Clin Oncol (R Coll Radiol) 2010, 22(6):486-497.
• [14]Wallin G, Lundell G, Tennvall J: Anaplastic giant cell thyroid carcinoma. Scand J Surg 2004, 93:272-277.
• [15]Levendag PC, Porre PM, de van Putten WL: Anaplastic carcinoma of the thyroid gland treated by radiation therapy. Int J Radiat Oncol Biol Phys 1993, 1993(26):125-128.
• [16]Wang Y, Tsang R, Asa S, Dickson B, Arenovich T, Brierley J: Clinical outcome of anaplastic thyroid carcinoma treated with radiotherapy of once- and twice-daily fractionation regimens. Cancer 2006, 107(8):1786-1792.
• [17]Tennvall J, Lundell G, Wahlberg P, Bergenfelz A, Grimelius L, Akerman M, Hjelm-Skog AL, Wallin G: Anaplastic thyroid carcinoma: three protocols combining doxorubicin, hyperfractionated radiotherapy and surgery. Brit J Cancer 2002, 86(12):1848-1853.
• [18]Kebebew E, Greenspan FS, Clark OH, Woeber KA, McMillan A: Anaplastic thyroid carcinoma: treatment outcome and prognostic factors. Cancer 2005, 103:1330-1335.
• [19]Kobayashi T, Asakawa H, Umeshita K, Takeda T, Maruyama H, Matsuzuka F, Monden M: Treatment of 37 patients with anaplastic carcinoma of the thyroid. Head Neck 1996, 18:36-41.
• [20]Junor EJ, Paul J, Reed NS: Anaplastic thyroid carcinoma: 91 patients treated by surgery and radiotherapy. Eur J Surg Oncol 1992, 18(2):83-88.
• [21]Alfano RW, Leppla SH, Liu S, Bugge TH, Ortiz JM, Lairmore TC, Duesbery NS, Mitchell IC, Nwariaku F, Frankel AE: Inhibition of tumor angiogenesis by the matrix metalloproteinase-activated anthrax lethal toxin in an orthotopic model of anaplastic thyroid carcinoma. Mol Cancer Ther 2010, 9(1):190-201.
• [22]Perri F, Di Lorenzo G, Della Vittoria Scarpati G, Buonerba C: Anaplastic thyroid carcinoma: a comprehensive review of current and future therapeutic options. World J Clin Oncol 2011, 2(3):150-157.
• [23]Matuszczyk A, Mann K: Neue Therapieformen beim Schilddrüsenkarzinom. Onkologe 2010, 16(7):690-694.
• [24]Mitsiades CS, McMillin D, Kotoula V, Poulaki V, McMullan C, Negri J, Fanourakis G, Tseleni-Balafouta S, Ain KB, Mitsiades N: Antitumor effects of the proteasome inhibor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro. J Clin Endocrinol Metab 2006, 91(10):4013-4021.
• [25]Besic N, Auersperg M, Us-Krasovec M, Golouh R, Frkovic-Grazio S, Vodnik A: Effect of primary treatment on survival in anaplastic thyroid carcinoma. Eur J Surg Oncol 2001, 27:260-264.
• [26]De Crevoisier R, Baudin E, Bachelot A, Leboulleux S, Travagli JP, Caillou B, Schlumberger M: Combined treatment of anaplastic thyroid carcinoma with surgery, chemotherapy, and hyperfractionated accelerated external radiotherapy. Int J Radiat Oncol Biol Phys 2004, 60:1137-1143.
• [27]Haigh PI, Ituarte PH, Wu HS, Treseler PA, Posner MD, Quivey JM, Duh QY, Clark OH: Completely resected anaplastic thyroid carcinoma combined with adjuvant chemotherapy and irradiation is associated with prolonged survival. Cancer 2001, 91:2335-2342.
• [28]Vordermark D, Pelz T, Sieker F: Die Rolle der externen Strahlentherapie bei der Behandlung des Schilddrüsenkarzinoms. Onkologe 2010, 16:695-700.